drugset / Trial / NCT07308132
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.
Timeline
- Start
- 2026-01-20
- Primary completion
- 2028-08-31
- Completion
- 2029-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-87801493 | Unknown | — | Subcutaneous |
| Subject | JNJ-95566692 | Unknown | — | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | Oral |
| Background | Loncastuximab Tesirine | Other / unclassified | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Polatuzumab Vedotin | Other / unclassified | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | Oral |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |
| Background | Vincristine | Small molecule | — | Intravenous |